tiprankstipranks
Advertisement
Advertisement
Bolt Biotherapeutics reports Q3 EPS ($3.72), consensus ($5.39)
PremiumThe FlyBolt Biotherapeutics reports Q3 EPS ($3.72), consensus ($5.39)
7M ago
Bolt Biotherapeutics’ Pioneering Study on BDC-4182: A New Hope for Cancer Treatment
Premium
Company Announcements
Bolt Biotherapeutics’ Pioneering Study on BDC-4182: A New Hope for Cancer Treatment
7M ago
Buy Rating for Bolt Biotherapeutics: Innovative Cancer Treatment Approach and Strategic Financial Management
Premium
Ratings
Buy Rating for Bolt Biotherapeutics: Innovative Cancer Treatment Approach and Strategic Financial Management
8M ago
Cautious Hold Rating on Bolt Biotherapeutics Amid Uncertain Trial Outcomes and Financial Sustainability
PremiumRatingsCautious Hold Rating on Bolt Biotherapeutics Amid Uncertain Trial Outcomes and Financial Sustainability
10M ago
Bolt Biotherapeutics target adjusted to $75 at Lake Street after reverse split
Premium
The Fly
Bolt Biotherapeutics target adjusted to $75 at Lake Street after reverse split
10M ago
Bolt Biotherapeutics reports Q2 EPS ($4.46), consensus ($6.27)
Premium
The Fly
Bolt Biotherapeutics reports Q2 EPS ($4.46), consensus ($6.27)
10M ago
Bolt Biotherapeutics initiated with a Buy at Lake Street
PremiumThe FlyBolt Biotherapeutics initiated with a Buy at Lake Street
1y ago
Cautious Hold on Bolt Biotherapeutics Amid Awaited Phase 1 Data and Strategic Decisions
Premium
Ratings
Cautious Hold on Bolt Biotherapeutics Amid Awaited Phase 1 Data and Strategic Decisions
1y ago
Cautious Hold Rating on Bolt Biotherapeutics Amid Promising Clinical Data and Financial Uncertainty
Premium
Ratings
Cautious Hold Rating on Bolt Biotherapeutics Amid Promising Clinical Data and Financial Uncertainty
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100